Alzamend Neuro (NASDAQ: ALZN)
Alzamend Neuro Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alzamend Neuro Company Info
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
News & Analysis
Why Alzamend Neuro Stock Soared Today
The company hopes to advance the standard of care for people with dementia.
Why Alzamend Neuro Stock Fell More Than 14% Today
Investors have been driving it lower for over a month now, but the stock just reached a curious price level.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.